{
    "id": "correct_subsidiary_00054_0",
    "rank": 35,
    "data": {
        "url": "https://www.nature.com/articles/s41579-023-00865-7",
        "read_more_link": "",
        "language": "en",
        "title": "Pathogenesis, epidemiology and control of Group A Streptococcus infection",
        "top_image": "https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41579-023-00865-7/MediaObjects/41579_2023_865_Fig1_HTML.png",
        "meta_img": "https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41579-023-00865-7/MediaObjects/41579_2023_865_Fig1_HTML.png",
        "images": [
            "https://pubads.g.doubleclick.net/gampad/ad?iu=/285/naturereviews.microbiology/article&sz=728x90&c=252482198&t=pos%3Dtop%26type%3Darticle%26artid%3Ds41579-023-00865-7%26doi%3D10.1038/s41579-023-00865-7%26subjmeta%3D326,421,590,631%26kwrd%3DPathogens,Vaccines",
            "https://media.springernature.com/full/nature-cms/uploads/product/nrmicro/header-00028b1adf038b39a78a15ae2109e015.svg",
            "https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41598-020-79354-3/MediaObjects/41598_2020_79354_Fig1_HTML.png",
            "https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41467-023-43160-y/MediaObjects/41467_2023_43160_Fig1_HTML.png",
            "https://media.springernature.com/w215h120/springer-static/image/art%3Aplaceholder%2Fimages/placeholder-figure-nature.png",
            "https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41579-023-00865-7/MediaObjects/41579_2023_865_Fig1_HTML.png",
            "https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41579-023-00865-7/MediaObjects/41579_2023_865_Fig2_HTML.png",
            "https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41579-023-00865-7/MediaObjects/41579_2023_865_Fig3_HTML.png",
            "https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41579-023-00865-7/MediaObjects/41579_2023_865_Fig4_HTML.png",
            "https://pubads.g.doubleclick.net/gampad/ad?iu=/285/naturereviews.microbiology/article&sz=300x250&c=-1250722475&t=pos%3Dright%26type%3Darticle%26artid%3Ds41579-023-00865-7%26doi%3D10.1038/s41579-023-00865-7%26subjmeta%3D326,421,590,631%26kwrd%3DPathogens,Vaccines",
            "https://www.nature.com/static/images/logos/sn-logo-white-ea63208b81.svg",
            "https://www.nature.com/static/images/logos/nature-briefing-microbiology-logo-3fa570e5fb.svg",
            "https://verify.nature.com/verify/nature.png",
            "https://www.nature.com/r7almjlk/article/s41579-023-00865-7"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Rivera-Hernandez",
            "Bodie F",
            "Harbison-Price",
            "De Oliveira",
            "David M. P",
            "Magnus G",
            "Mark R",
            "Mark J"
        ],
        "publish_date": "2023-03-09T00:00:00",
        "summary": "",
        "meta_description": "Streptococcus pyogenes (Group A Streptococcus; GAS) is exquisitely adapted to the human host, resulting in asymptomatic infection, pharyngitis, pyoderma, scarlet fever or invasive diseases, with potential for triggering post-infection immune sequelae. GAS deploys a range of virulence determinants to allow colonization, dissemination within the host and transmission, disrupting both innate and adaptive immune responses to infection. Fluctuating global GAS epidemiology is characterized by the emergence of new GAS clones, often associated with the acquisition of new virulence or antimicrobial determinants that are better adapted to the infection niche or averting host immunity. The recent identification of clinical GAS isolates with reduced penicillin sensitivity and increasing macrolide resistance threatens both frontline and penicillin-adjunctive antibiotic treatment. The World Health Organization (WHO) has developed a GAS research and technology road map and has outlined preferred vaccine characteristics, stimulating renewed interest in the development of safe and effective GAS vaccines. In this Review, Brouwer et al. summarize recent developments in our understanding of Group A Streptococcus (GAS), focusing on the epidemiologic and clinical features of GAS infection and the molecular mechanisms associated with GAS virulence and drug resistance.",
        "meta_lang": "en",
        "meta_favicon": "/static/images/favicons/nature/apple-touch-icon-f39cb19454.png",
        "meta_site_name": "Nature",
        "canonical_link": "https://www.nature.com/articles/s41579-023-00865-7",
        "text": "Walker, M. J. et al. Disease manifestations and pathogenic mechanisms of Group A Streptococcus. Clin. Microbiol. Rev. 27, 264–301 (2014).\n\nMcMillan, D. J. et al. Updated model of Group A Streptococcus M proteins based on a comprehensive worldwide study. Clin. Microbiol. Infect. 19, E222–E229 (2013).\n\nSteer, A. C., Law, I., Matatolu, L., Beall, B. W. & Carapetis, J. R. Global emm type distribution of Group A streptococci: systematic review and implications for vaccine development. Lancet Infect. Dis. 9, 611–616 (2009).\n\nLynskey, N. N. et al. Emergence of dominant toxigenic M1T1 Streptococcus pyogenes clone during increased scarlet fever activity in England: a population-based molecular epidemiological study. Lancet Infect. Dis. 19, 1209–1218 (2019). This paper reports a dominant new emm1 GAS lineage (M1UK) that is characterized by increased SpeA production, which may be contributing to the upsurge of scarlet fever and invasive infections in England.\n\nTse, H. et al. Molecular characterization of the 2011 Hong Kong scarlet fever outbreak. J. Infect. Dis. 206, 341–351 (2012).\n\nDavies, M. R. et al. Emergence of scarlet fever Streptococcus pyogenes emm12 clones in Hong Kong is associated with toxin acquisition and multidrug resistance. Nat. Genet. 47, 84–87 (2015).\n\nTurner, C. E. et al. Scarlet fever upsurge in England and molecular-genetic analysis in North-West London, 2014. Emerg. Infect. Dis. 22, 1075–1078 (2016).\n\nDeng, W. et al. Streptococcal pyrogenic exotoxin B cleaves GSDMA and triggers pyroptosis. Nature 602, 496–502 (2022). This paper reports demonstrating that SpeB triggers keratinocyte pyroptosis by cleaving GSDMA, providing a mechanism for inflammatory response stimulation at the epithelial cell layer.\n\nLaRock, D. L. et al. Group A Streptococcus induces GSDMA-dependent pyroptosis in keratinocytes. Nature 605, 527–531 (2022). This paper demonstrates the roles of SpeB in caspase 1-independent activation of GSDMA in skin cells.\n\nEmgård, J. et al. MAIT cells are major contributors to the cytokine response in Group A streptococcal toxic shock syndrome. Proc. Natl Acad. Sci. USA 116, 25923–25931 (2019).\n\nMusser, J. M. et al. Reduced in vitro susceptibility of Streptococcus pyogenes to β-lactam antibiotics associated with mutations in the pbp2x gene is geographically widespread. J. Clin. Microbiol. 58, e01993-19 (2020).\n\nHayes, A., Lacey, J. A., Morris, J. M., Davies, M. R. & Tong, S. Y. C. Restricted sequence variation in Streptococcus pyogenes penicillin binding proteins. mSphere 5, e00090-20 (2020).\n\nChochua, S. et al. Population and whole genome sequence based characterization of invasive Group A streptococci recovered in the United States during 2015. mBio 8, e01422-17 (2017). This work presents a detailed large-scale population-based genomic characterization of invasive GAS isolates in the United States.\n\nVannice, K. S. et al. Streptococcus pyogenes pbp2x mutation confers reduced susceptibility to β-lactam antibiotics. Clin. Infect. Dis. 71, 201–204 (2020).\n\nChochua, S. et al. Invasive Group A streptococcal penicillin binding protein 2x variants associated with reduced susceptibility to β-lactam antibiotics in the United States, 2015–2021. Antimicrob. Agents Chemother. 66, e0080222 (2022).\n\nVekemans, G. R. & Kim The path to Group A Streptococcus vaccines: WHO research and development technology roadmap and preferred product characteristics. Clin. Infect. Dis. 69, 877–883 (2019).\n\nDavies, M. R. et al. Atlas of Group A streptococcal vaccine candidates compiled using large-scale comparative genomics. Nat. Genet. 51, 1035–1043 (2019). This study uses global GAS genomic data sets to develop a platform for genomics-informed vaccine design.\n\nDale, J. B. & Walker, M. J. Update on Group A streptococcal vaccine development. Curr. Opin. Infect. Dis. 33, 244–250 (2020).\n\nRivera-Hernandez, T. et al. An experimental Group A Streptococcus vaccine that reduces pharyngitis and tonsillitis in a nonhuman primate model. mBio 10, e00693-19 (2019).\n\nOsowicki, J. et al. A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study. Lancet Microbe 2, e291–e299 (2021). This landmark paper reports the first controlled GAS human infection model of pharyngitis.\n\nHand, R. M., Snelling, T. L. & Carapetis, J. R. Group A Streptococcus. in Hunter’s Tropical Medicine and Emerging Infectious Diseases (eds Ryan, E. T., Hill, D. R., Solomon, T., Aronson, N. E. & Endy, T. P.) 429–438 (Elsevier, 2020).\n\nMiller, K. M. et al. The global burden of sore throat and Group A Streptococcus pharyngitis: a systematic review and meta-analysis. EClinicalMedicine 48, 101458 (2022).\n\nCannon, J. W. et al. The economic and health burdens of diseases caused by Group A Streptococcus in New Zealand. Int. J. Infect. Dis. 103, 176–181 (2021).\n\nOrdunez, P. et al. Rheumatic heart disease burden, trends, and inequalities in the Americas, 1990–2017: a population-based study. Lancet Glob. Health 7, e1388–e1397 (2019).\n\nLv, M. et al. Global burden of rheumatic heart disease and its association with socioeconomic development status, 1990–2019. Eur. J. Prev. Cardiol. 29, 1425–1434 (2022).\n\nde Loizaga, S. R. et al. Rheumatic heart disease in the United States: forgotten but not gone: results of a 10 year multicenter review. J. Am. Heart Assoc. 10, e020992 (2021).\n\nOliver, J. et al. Preceding Group A Streptococcus skin and throat infections are individually associated with acute rheumatic fever: evidence from New Zealand. BMJ Glob. Health 6, e007038 (2021).\n\nBarth, D. D. et al. Missing piece study protocol: prospective surveillance to determine the epidemiology of Group A streptococcal pharyngitis and impetigo in remote Western Australia. BMJ Open 12, e057296 (2022).\n\nPark, D. W. et al. Incidence and characteristics of scarlet fever, South Korea, 2008–2015. Emerg. Infect. Dis. 23, 658–661 (2017).\n\nYung, C. F. & Thoon, K. C. A 12 year outbreak of scarlet fever in Singapore. Lancet Infect. Dis. 18, 942 (2018).\n\nLamagni, T. et al. Resurgence of scarlet fever in England, 2014–16: a population-based surveillance study. Lancet Infect. Dis. 18, 180–187 (2018).\n\nCubria, M. B., Delgado, J., Shah, B. J., Sanson, M. A. & Flores, A. R. Identification of epidemic scarlet fever Group A Streptococcus strains in the paediatric population of Houston, TX, USA. Access. Microbiol. 3, 000274 (2021).\n\nWalker, M. J. et al. Detection of epidemic scarlet fever Group A Streptococcus in Australia. Clin. Infect. Dis. 69, 1232–1234 (2019).\n\nWatts, V. et al. Increased risk for invasive Group A Streptococcus disease for household contacts of scarlet fever cases, England, 2011–2016. Emerg. Infect. Dis. 25, 529–537 (2019).\n\nRon, M. et al. Invasive multidrug-resistant emm93.0 Streptococcus pyogenes strain harboring a novel genomic island, Israel, 2017–2019. Emerg. Infect. Dis. 28, 118–126 (2022).\n\nTyrrell, G. J., Bell, C., Bill, L. & Fathima, S. Increasing incidence of invasive Group A Streptococcus disease in first nations population, Alberta, Canada, 2003–2017. Emerg. Infect. Dis. 27, 443–451 (2021).\n\nValenciano, S. J. et al. Invasive Group A streptococcal infections among people who inject drugs and people experiencing homelessness in the United States, 2010–2017. Clin. Infect. Dis. 73, e3718–e3726 (2021).\n\nPhillips, G. N. Jr, Flicker, P. F., Cohen, C., Manjula, B. N. & Fischetti, V. A. Streptococcal M protein: α-helical coiled-coil structure and arrangement on the cell surface. Proc. Natl Acad. Sci. USA 78, 4689–4693 (1981).\n\nLi, Z. et al. Array of M protein gene subtypes in 1064 recent invasive Group A Streptococcus isolates recovered from the active bacterial core surveillance. J. Infect. Dis. 188, 1587–1592 (2003).\n\nValderrama, J. A. et al. Group A streptococcal M protein activates the NLRP3 inflammasome. Nat. Microbiol. 2, 1425–1434 (2017). This comprehensive report demonstrates that M1 protein triggers caspase 1-dependent NLRP3 inflammasome activation, leading to pyroptotic macrophage cell death.\n\nRichter, J. et al. Streptolysins are the primary inflammasome activators in macrophages during Streptococcus pyogenes infection. Immunol. Cell Biol. 99, 1040–1052 (2021).\n\nOkada, N., Liszewski, M. K., Atkinson, J. P. & Caparon, M. Membrane cofactor protein (CD46) is a keratinocyte receptor for the M protein of the Group A Streptococcus. Proc. Natl Acad. Sci. USA 92, 2489–2493 (1995).\n\nRyan, P. A., Pancholi, V. & Fischetti, V. A. Group A streptococci bind to mucin and human pharyngeal cells through sialic acid-containing receptors. Infect. Immun. 69, 7402–7412 (2001).\n\nDe Oliveira, D. M. et al. Blood group antigen recognition via the Group A streptococcal M protein mediates host colonization. mBio 8, e02237-16 (2017).\n\nFeito, M. J. et al. Membrane cofactor protein (MCP, CD46) binding to clinical isolates of Streptococcus pyogenes: binding to M type 18 strains is independent of Emm or Enn proteins. Mol. Immunol. 44, 3571–3579 (2007).\n\nAruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B. & Seed, B. CD44 is the principal cell surface receptor for hyaluronate. Cell 61, 1303–1313 (1990).\n\nCywes, C. & Wessels, M. R. Group A Streptococcus tissue invasion by CD44-mediated cell signalling. Nature 414, 648–652 (2001).\n\nWessels, M. R. Capsular polysaccharide of Group A Streptococcus. Microbiol. Spectr. 7, https://doi.org/10.1128/microbiolspec.GPP3-0050-2018 (2019).\n\nFlores, A. R., Jewell, B. E., Fittipaldi, N., Beres, S. B. & Musser, J. M. Human disease isolates of serotype M4 and M22 Group A Streptococcus lack genes required for hyaluronic acid capsule biosynthesis. mBio 3, e00413–12 (2012).\n\nTurner, C. E. et al. Emergence of a new highly successful acapsular Group A Streptococcus clade of genotype emm89 in the United Kingdom. mBio 6, e00622 (2015).\n\nFlores, A. R., Chase McNeil, J., Shah, B., Van Beneden, C. & Shelburne, S. A. Capsule-negative emm types are an increasing cause of pediatric Group A streptococcal infections at a large pediatric hospital in Texas. J. Pediatr. Infect. Dis. Soc. 8, 244–250 (2019).\n\nTurner, C. E. et al. The emergence of successful Streptococcus pyogenes lineages through convergent pathways of capsule loss and recombination directing high toxin expression. mBio 10, e02521-19 (2019).\n\nWierzbicki, I. H. et al. Group A streptococcal S protein utilizes red blood cells as immune camouflage and is a critical determinant for immune evasion. Cell Rep. 29, 2979–2989.e15 (2019). This study utilizes biomimetic virulomics to show that GAS S protein captures lysed red blood cell membranes to cloak the bacterial cell surface, which allows bacteria to evade host immunity.\n\nPotempa, J. & Pike, R. N. Corruption of innate immunity by bacterial proteases. J. Innate Immun. 1, 70–87 (2009).\n\nEdwards, R. J. et al. Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J. Infect. Dis. 192, 783–790 (2005).\n\nCleary, P. P., Prahbu, U., Dale, J. B., Wexler, D. E. & Handley, J. Streptococcal C5a peptidase is a highly specific endopeptidase. Infect. Immun. 60, 5219–5223 (1992).\n\nRemmington, A. & Turner, C. E. The DNases of pathogenic Lancefield streptococci. Microbiology 164, 242–250 (2018).\n\nSumby, P. et al. Extracellular deoxyribonuclease made by Group A Streptococcus assists pathogenesis by enhancing evasion of the innate immune response. Proc. Natl Acad. Sci. USA 102, 1679–1684 (2005).\n\nHasegawa, T. et al. Characterization of a virulence-associated and cell-wall-located DNase of Streptococcus pyogenes. Microbiology 156, 184–190 (2010).\n\nBuchanan, J. T. et al. DNase expression allows the pathogen Group A Streptococcus to escape killing in neutrophil extracellular traps. Curr. Biol. 16, 396–400 (2006).\n\nBrouwer, S. et al. Prophage exotoxins enhance colonization fitness in epidemic scarlet fever-causing Streptococcus pyogenes. Nat. Commun. 11, 5018 (2020). This paper reports the thiol-activated bacterial superantigen, showcasing the relationship between prophage exotoxins and virulence phenotypes of scarlet fever-causing GAS.\n\nTanaka, M. et al. Group A Streptococcus establishes pharynx infection by degrading the deoxyribonucleic acid of neutrophil extracellular traps. Sci. Rep. 10, 3251 (2020).\n\nUchiyama, S., Andreoni, F., Schuepbach, R. A., Nizet, V. & Zinkernagel, A. S. DNase Sda1 allows invasive M1T1 Group A Streptococcus to prevent TLR9-dependent recognition. PLoS Pathog. 8, e1002736 (2012).\n\nKhil, J. et al. Plasminogen enhances virulence of Group A streptococci by streptokinase-dependent and streptokinase-independent mechanisms. J. Infect. Dis. 188, 497–505 (2003).\n\nSun, H. et al. Plasminogen is a critical host pathogenicity factor for Group A streptococcal infection. Science 305, 1283–1286 (2004).\n\nMcArthur, J. D. et al. Allelic variants of streptokinase from Streptococcus pyogenes display functional differences in plasminogen activation. FASEB J. 22, 3146–3153 (2008).\n\nNitzsche, R., Kohler, J., Kreikemeyer, B. & Oehmcke-Hecht, S. Streptococcus pyogenes escapes killing from extracellular histones through plasminogen binding and activation by streptokinase. J. Innate Immun. 8, 589–600 (2016).\n\nVincents, B., von Pawel-Rammingen, U., Bjorck, L. & Abrahamson, M. Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding. Biochemistry 43, 15540–15549 (2004).\n\nAgniswamy, J., Lei, B., Musser, J. M. & Sun, P. D. Insight of host immune evasion mediated by two variants of Group A Streptococcus Mac protein. J. Biol. Chem. 279, 52789–52796 (2004).\n\nNaegeli, A. et al. Streptococcus pyogenes evades adaptive immunity through specific IgG glycan hydrolysis. J. Exp. Med. 216, 1615–1629 (2019).\n\nSumitomo, T., Nakata, M., Higashino, M., Terao, Y. & Kawabata, S. Group A streptococcal cysteine protease cleaves epithelial junctions and contributes to bacterial translocation. J. Biol. Chem. 288, 13317–13324 (2013).\n\nKapur, V. et al. A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin. Microb. Pathog. 15, 327–346 (1993).\n\nTerao, Y. et al. Group A streptococcal cysteine protease degrades C3 (C3b) and contributes to evasion of innate immunity. J. Biol. Chem. 283, 6253–6260 (2008).\n\nSchmidtchen, A., Frick, I. M., Andersson, E., Tapper, H. & Bjorck, L. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol. Microbiol. 46, 157–168 (2002).\n\nBarnett, T. C. et al. The globally disseminated M1T1 clone of Group A Streptococcus evades autophagy for intracellular replication. Cell Host Microbe 14, 675–682 (2013).\n\nEgesten, A. et al. SpeB of Streptococcus pyogenes differentially modulates antibacterial and receptor activating properties of human chemokines. PLoS ONE 4, e4769 (2009).\n\nKapur, V., Majesky, M. W., Li, L. L., Black, R. A. & Musser, J. M. Cleavage of interleukin 1β (IL-1β) precursor to produce active IL-1β by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc. Natl Acad. Sci. USA 90, 7676–7680 (1993).\n\nMacleod, T. et al. The proinflammatory cytokine IL-36γ is a global discriminator of harmless microbes and invasive pathogens within epithelial tissues. Cell Rep. 33, 108515 (2020). This important study demonstrates that epithelial cytokine IL-36γ is a global sensor of pathogen-derived proteases during epithelial infection.\n\nKansal, R. G., McGeer, A., Low, D. E., Norrby-Teglund, A. & Kotb, M. Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive Group A streptococcal infection cases. Infect. Immun. 68, 6362–6369 (2000).\n\nSumby, P., Whitney, A. R., Graviss, E. A., DeLeo, F. R. & Musser, J. M. Genome-wide analysis of Group A streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog. 2, e5 (2006).\n\nWalker, M. J. et al. DNase Sda1 provides selection pressure for a switch to invasive Group A streptococcal infection. Nat. Med. 13, 981–985 (2007). This comprehensive report details the molecular basis of natural selection of hypervirulent bacterial variants with increased risk of systemic dissemination.\n\nMaamary, P. G. et al. Parameters governing invasive disease propensity of non-M1 serotype Group A streptococci. J. Innate Immun. 2, 596–606 (2010).\n\nCole, J. N. et al. Trigger for Group A streptococcal M1T1 invasive disease. FASEB J. 20, 1745–1747 (2006).\n\nMolloy, E. M., Cotter, P. D., Hill, C., Mitchell, D. A. & Ross, R. P. Streptolysin S-like virulence factors: the continuing sagA. Nat. Rev. Microbiol. 9, 670–681 (2011).\n\nSierig, G., Cywes, C., Wessels, M. R. & Ashbaugh, C. D. Cytotoxic effects of streptolysin O and streptolysin S enhance the virulence of poorly encapsulated Group A streptococci. Infect. Immun. 71, 446–455 (2003).\n\nFlaherty, R. A., Puricelli, J. M., Higashi, D. L., Park, C. J. & Lee, S. W. Streptolysin S promotes programmed cell death and enhances inflammatory signaling in epithelial keratinocytes during Group A Streptococcus infection. Infect. Immun. 83, 4118–4133 (2015).\n\nUchiyama, S. et al. Streptolysin O rapidly impairs neutrophil oxidative burst and antibacterial responses to Group A. Streptococcus. Front. Immunol. 6, 581 (2015).\n\nGoldmann, O., Sastalla, I., Wos-Oxley, M., Rohde, M. & Medina, E. Streptococcus pyogenes induces oncosis in macrophages through the activation of an inflammatory programmed cell death pathway. Cell. Microbiol. 11, 138–155 (2009).\n\nPinho-Ribeiro, F. A. et al. Blocking neuronal signaling to immune cells treats streptococcal invasive infection. Cell 173, 1083–1097 e22 (2018). This work demonstrates how GAS exploits neuro-immunological signalling to cause invasive infection.\n\nKimoto, H., Fujii, Y., Yokota, Y. & Taketo, A. Molecular characterization of NADase–streptolysin O operon of hemolytic streptococci. Biochim. Biophys. Acta 1681, 134–149 (2005).\n\nMichos, A. et al. Enhancement of streptolysin O activity and intrinsic cytotoxic effects of the Group A streptococcal toxin, NAD-glycohydrolase. J. Biol. Chem. 281, 8216–8223 (2006).\n\nVelarde, J. J., O’Seaghdha, M., Baddal, B., Bastiat-Sempe, B. & Wessels, M. R. Binding of NAD+-glycohydrolase to streptolysin O stabilizes both toxins and promotes virulence of Group A Streptococcus. mBio 8, e01382-17 (2017).\n\nVelarde, J. J. et al. Structure of the Streptococcus pyogenes NAD+ glycohydrolase translocation domain and its essential role in toxin binding to oropharyngeal keratinocytes. J. Bacteriol. 204, e0036621 (2022).\n\nMagassa, N., Chandrasekaran, S. & Caparon, M. G. Streptococcus pyogenes cytolysin-mediated translocation does not require pore formation by streptolysin O. EMBO Rep. 11, 400–405 (2010).\n\nO’Seaghdha, M. & Wessels, M. R. Streptolysin O and its co-toxin NAD-glycohydrolase protect Group A Streptococcus from xenophagic killing. PLoS Pathog. 9, e1003394 (2013).\n\nBastiat-Sempe, B., Love, J. F., Lomayesva, N. & Wessels, M. R. Streptolysin O and NAD-glycohydrolase prevent phagolysosome acidification and promote Group A Streptococcus survival in macrophages. mBio 5, e01690-14 (2014).\n\nNozawa, T. et al. Intracellular Group A Streptococcus induces golgi fragmentation to impair host defenses through streptolysin O and NAD-glycohydrolase. mBio 12, e01974-20 (2021).\n\nZhu, L. et al. Contribution of secreted NADase and streptolysin O to the pathogenesis of epidemic serotype M1 Streptococcus pyogenes infections. Am. J. Pathol. 187, 605–613 (2017).\n\nNasser, W. et al. Evolutionary pathway to increased virulence and epidemic Group A Streptococcus disease derived from 3,615 genome sequences. Proc. Natl Acad. Sci. USA 111, E1768–E1776 (2014).\n\nZhu, L. et al. A molecular trigger for intercontinental epidemics of Group A Streptococcus. J. Clin. Invest. 125, 3545–3559 (2015).\n\nMcCormick, J. K., Yarwood, J. M. & Schlievert, P. M. Toxic shock syndrome and bacterial superantigens: an update. Annu. Rev. Microbiol. 55, 77–104 (2001).\n\nReglinski, M., Sriskandan, S. & Turner, C. E. Identification of two new core chromosome-encoded superantigens in Streptococcus pyogenes; speQ and speR. J. Infect. 78, 358–363 (2019).\n\nKasper, K. J. et al. Bacterial superantigens promote acute nasopharyngeal infection by Streptococcus pyogenes in a human MHC class II-dependent manner. PLoS Pathog. 10, e1004155 (2014). This paper presents clear evidence that streptococcal superantigens are critical for the establishment of acute infection of the upper respiratory tract by GAS.\n\nSriskandan, S. et al. Enhanced susceptibility to superantigen-associated streptococcal sepsis in human leukocyte antigen-DQ transgenic mice. J. Infect. Dis. 184, 166–173 (2001).\n\nAnderson, J. et al. Immune signature of acute pharyngitis in a Streptococcus pyogenes human challenge trial. Nat. Commun. 13, 769 (2022).\n\nDan, J. M. et al. Recurrent Group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant TFH cells. Sci. Transl. Med. 11, eaau3776 (2019).\n\nLe Bourhis, L. et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat. Immunol. 11, 701–708 (2010). This study demonstrates that mucosal-associated invariant T lymphocytes (MAIT lymphocytes) are evolutionarily conserved innate-like T cells that sense and help fight microbial infection.\n\nMeermeier, E. W. et al. Human TRAV1-2-negative MR1-restricted T cells detect S. pyogenes and alternatives to MAIT riboflavin-based antigens. Nat. Commun. 7, 12506 (2016).\n\nShaler, C. R. et al. MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function: defining a novel mechanism of superantigen-induced immunopathology and immunosuppression. PLoS Biol. 15, e2001930 (2017).\n\nTilahun, A. Y., Holz, M., Wu, T.-T., David, C. S. & Rajagopalan, G. Interferon γ-dependent intestinal pathology contributes to the lethality in bacterial superantigen-induced toxic shock syndrome. PLoS ONE 6, e16764 (2011).\n\nOzkaya, M. et al. The number and activity of CD3 TCR Vα7.2 CD161 cells are increased in children with acute rheumatic fever. Int. J. Cardiol. 333, 174–183 (2021).\n\nTeker, E. et al. Association between the interferon γ 874 T/A polymorphism and the severity of valvular damage in patients with rheumatic heart disease. Biochem. Genet. 56, 225–234 (2018).\n\nGuilherme, L. et al. Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am. J. Pathol. 165, 1583–1591 (2004).\n\nRouxel, O. et al. Author Correction: cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes. Nat. Immunol. 19, 1035 (2018).\n\nBianchi, E., Rogge, L. & Vecellio, M. Role of the IL-23/IL-17 pathway in chronic immune-mediated inflammatory diseases: mechanisms and targeted therapies. Front. Immunol. 12, 770275 (2021).\n\nHaga, K. et al. MAIT cells are activated and accumulated in the inflamed mucosa of ulcerative colitis. J. Gastroenterol. Hepatol. 31, 965–972 (2016).\n\nThompson, K. M., Sterkel, A. K., McBride, J. A. & Corliss, R. F. The shock of strep: rapid deaths due to Group A Streptococcus. Acad. Forensic Pathol. 8, 136–149 (2018).\n\nCatafal-Tardos, E., Baglioni, M. V. & Bekiaris, V. Inhibiting the unconventionals: importance of immune checkpoint receptors in γδ T, MAIT, and NKT cells. Cancers 13, 4647 (2021).\n\nKim, M. L. et al. Dysregulated IL-1β–GM–CSF axis in acute rheumatic fever that is limited by hydroxychloroquine. Circulation 138, 2648–2661 (2018).\n\nNoster, R. et al. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci. Transl. Med. 6, 80 (2014).\n\nWang, J. & Han, B. Dysregulated CD4+ T cells and microRNAs in myocarditis. Front. Immunol. 11, 539 (2020).\n\nMyers, J. M. et al. Cardiac myosin-TH17 responses promote heart failure in human myocarditis. JCI Insight 1, e85851 (2016).\n\nFaé, K. C. et al. CXCL9/Mig mediates T cells recruitment to valvular tissue lesions of chronic rheumatic heart disease patients. Inflammation 36, 800–811 (2013).\n\nHansen, M. B. et al. Association between cytokine response, the LRINEC score and outcome in patients with necrotising soft tissue infection: a multicentre, prospective study. Sci. Rep. 7, 42179 (2017).\n\nLancefield, R. C. The antigenic complex of Streptococcus haemolyticus: specific substance in extracts of Streptococcus haemolyticus. J. Exp. Med. 47, 91–103 (1928).\n\nBeall, B., Facklam, R. & Thompson, T. Sequencing emm-specific PCR products for routine and accurate typing of Group A streptococci. J. Clin. Microbiol. 34, 953–958 (1996).\n\nWhatmore, A. M., Kapur, V., Sullivan, D. J., Musser, J. M. & Kehoe, M. A. Non-congruent relationships between variation in emm gene sequences and the population genetic structure of Group A streptococci. Mol. Microbiol. 14, 619–631 (1994).\n\nFriães, A., Mamede, R., Ferreira, M., Melo-Cristino, J. & Ramirez, M. Annotated whole-genome multilocus sequence typing schema for scalable high-resolution typing of Streptococcus pyogenes. J. Clin. Microbiol. 60, e0031522 (2022).\n\nJespersen, M. G., Lacey, J. A., Tong, S. Y. C. & Davies, M. R. Global genomic epidemiology of Streptococcus pyogenes. Infect. Genet. Evol. 86, 104609 (2020).\n\nBessen, D. E., Smeesters, P. R. & Beall, B. W. Molecular epidemiology, ecology, and evolution of Group A streptococci. Microbiol. Spectr. 6, https://doi.org/10.1128/microbiolspec.CPP3-0009-2018 (2018).\n\nBessen, D. E. et al. Molecular epidemiology and genomics of Group A Streptococcus. Infect. Genet. Evol. 33, 393–418 (2015).\n\nBah, S. Y. et al. Genomic characterization of skin and soft tissue Streptococcus pyogenes isolates from a low-income and a high-income setting. mSphere 8, e0046922 (2022).\n\nSeale, A. C. et al. Invasive Group A Streptococcus infection among children, rural Kenya. Emerg. Infect. Dis. 22, 224–232 (2016).\n\nBowen, A. C. et al. Whole genome sequencing reveals extensive community-level transmission of Group A Streptococcus in remote communities. Epidemiol. Infect. 144, 1991–1998 (2016).\n\nLi, Y., Nanduri, S. A., Van Beneden, C. A. & Beall, B. W. M1 lineage in invasive Group A Streptococcus isolates from the USA. Lancet Infect. Dis. 20, 538–539 (2020).\n\nRümke, L. W. et al. Dominance of M1 clade among dutch M1 Streptococcus pyogenes. Lancet Infect. Dis. 20, 539–540 (2020).\n\nDemczuk, W., Martin, I., Domingo, F. R., MacDonald, D. & Mulvey, M. R. Identification of Streptococcus pyogenes M1 clone in Canada. Lancet Infect. Dis. 19, 1284–1285 (2019).\n\nMetcalf, B. et al. Cluster transmission drives invasive Group A Streptococcus disease within the United States and is focused on communities experiencing disadvantage. J. Infect. Dis. 226, 546–553 (2022).\n\nLi, Y. et al. Genomic characterization of Group A streptococci causing pharyngitis and invasive disease in Colorado, USA, June 2016–April 2017. J. Infect. Dis. 225, 1841–1851 (2022).\n\nNabarro, L. E. et al. Invasive Group A Streptococcus outbreaks associated with home healthcare, England, 2018–2019. Emerg. Infect. Dis. 28, 915–923 (2022).\n\nNanduri, S. A. et al. Prolonged and large outbreak of invasive Group A Streptococcus disease within a nursing home: repeated intrafacility transmission of a single strain. Clin. Microbiol. Infect. 25, 248.e1–248.e7 (2019).\n\nCordery, R. et al. Frequency of transmission, asymptomatic shedding, and airborne spread of Streptococcus pyogenes in schoolchildren exposed to scarlet fever: a prospective, longitudinal, multicohort, molecular epidemiological, contact-tracing study in England, UK. Lancet Microbe 3, e366–e375 (2022).\n\nRalph, A. P. et al. Evaluation of a community-led program for primordial and primary prevention of rheumatic fever in remote Northern Australia. Int. J. Environ. Res. Public. Health 19, 10215 (2022).\n\nBabiker, A. et al. Effectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study. Lancet Infect. Dis. 21, 697–710 (2021).\n\nGastanaduy, A. S., Huwe, B. B., Wannamaker, L. W., Kaplan, E. L. & Mckay, C. Failure of penicillin to eradicate Group A streptococci during an outbreak of pharyngitis. Lancet 2, 498–502 (1980).\n\nKaplan, E. L. & Johnson, D. R. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of Group A streptococci from children with acute pharyngitis. Pediatrics 108, 1180–1186 (2001).\n\nHorn, D. L. et al. Outcomes of β-hemolytic streptococcal necrotizing skin and soft-tissue infections and the impact of clindamycin resistance. Clin. Infect. Dis. 73, e4592–e4598 (2021).\n\nSeppala, H., Skurnik, M., Soini, H., Roberts, M. C. & Huovinen, P. A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pyogenes. Antimicrob. Agents Chemother. 42, 257–262 (1998).\n\nChancey, S. T. et al. Composite mobile genetic elements disseminating macrolide resistance in Streptococcus pneumoniae. Front. Microbiol. 6, 26 (2015).\n\nOppegaard, O., Skrede, S., Mylvaganam, H. & Kittang, B. R. Emerging threat of antimicrobial resistance in β-hemolytic streptococci. Front. Microbiol. 11, 797 (2020).\n\nWoodbury, R. L. et al. Plasmid-borne erm(T) from invasive, macrolide-resistant Streptococcus pyogenes strains. Antimicrob. Agents Chemother. 52, 1140–1143 (2008).\n\nLi, Y. et al. Continued increase of erythromycin nonsusceptibility and clindamycin nonsusceptibility among invasive Group A streptococci driven by genomic clusters, USA, 2018–2019. Clin. Infect. Dis. 76, e1266–e1269 (2023).\n\nLewis, J. S. et al. Failure of clindamycin to eradicate infection with β-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections. Antimicrob. Agents Chemother. 58, 1327–1331 (2014).\n\nYu, D. L., Liang, Y. M., Zheng, Y. J. & Yang, Y. H. Clindamycin-resistant Streptococcus pyogenes in Chinese children. Lancet Infect. Dis. 21, 1631–1632 (2021).\n\nClancy, J. et al. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Mol. Microbiol. 22, 867–879 (1996).\n\nCenters for Disease Control and Prevention. Active bacterial core surveillance (ABCs). CDC https://www.cdc.gov/abcs/reports-findings/surv-reports.html (2019).\n\nFay, K. et al. Patterns of antibiotic nonsusceptibility among invasive Group A Streptococcus infections — United States, 2006–2017. Clin. Infect. Dis. 73, 1957–1964 (2021).\n\nBruun, T. et al. Risk factors and predictors of mortality in streptococcal necrotizing soft-tissue infections: a multicenter prospective study. Clin. Infect. Dis. 72, 293–300 (2021).\n\nSilva-Costa, C., Pinto, F. R., Ramirez, M. & Melo-Cristino, J., Portuguese Surveillance Group for the Study of Respiratory Pathogens. Decrease in macrolide resistance and clonal instability among Streptococcus pyogenes in Portugal. Clin. Microbiol. Infect. 14, 1152–1159 (2008).\n\nPerez-Trallero, E. et al. Phenotypic and genotypic characterization of Streptococcus pyogenes isolates displaying the MLSB phenotype of macrolide resistance in Spain, 1999 to 2005. Antimicrob. Agents Chemother. 51, 1228–1233 (2007).\n\nRodriguez-Avial, I., Rodriguez-Avial, C., Culebras, E. & Picazo, J. J. Distribution of tetracycline resistance genes tet(M), tet(O), tet(L) and tet(K) in blood isolates of viridans Group streptococci harbouring erm(B) and mef(A) genes. Susceptibility to quinupristin/dalfopristin and linezolid. Int. J. Antimicrob. Agents 21, 536–541 (2003).\n\nTsai, W. C. et al. Emergence of macrolide-resistant Streptococcus pyogenes emm12 in southern Taiwan from 2000 to 2019. J. Microbiol. Immunol. Infect. 54, 1086–1093 (2021).\n\nWajima, T. et al. Distribution of emm type and antibiotic susceptibility of Group A streptococci causing invasive and noninvasive disease. J. Med. Microbiol. 57, 1383–1388 (2008).\n\nTatara, K. et al. Molecular epidemiology, antimicrobial susceptibility, and characterization of fluoroquinolone non-susceptible Streptococcus pyogenes in Japan. J. Infect. Chemother. 26, 280–284 (2020).\n\nUbukata, K. et al. Changes in epidemiologic characteristics and antimicrobial resistance of Streptococcus pyogenes isolated over 10 years from Japanese children with pharyngotonsillitis. J. Med. Microbiol. 69, 443–450 (2020).\n\nShen, Y. F. et al. Identification and characterization of fluoroquinolone non-susceptible Streptococcus pyogenes clones harboring tetracycline and macrolide resistance in Shanghai, China. Front. Microbiol. 9, 542 (2018).\n\nBrowne, A. J. et al. Global antibiotic consumption and usage in humans, 2000–18: a spatial modelling study. Lancet Planet. Health 5, e893–e904 (2021).\n\nGahlawat, G. et al. Emerging treatment strategies for impetigo in endemic and nonendemic settings: a systematic review. Clin. Ther. 43, 986–1006 (2021).\n\nHuovinen, P. Resistance to trimethoprim-sulfamethoxazole. Clin. Infect. Dis. 32, 1608–1614 (2001).\n\nBergmann, R., Sagar, V., Nitsche-Schmitz, D. P. & Chhatwal, G. D. First detection of trimethoprim resistance determinant dfrG in Streptococcus pyogenes clinical isolates in India. Antimicrob. Agents Chemother. 56, 5424–5425 (2012).\n\nRodrigo, M. K. D. et al. Host-dependent resistance of Group A Streptococcus to sulfamethoxazole mediated by a horizontally-acquired reduced folate transporter. Nat. Commun. 13, 6557 (2022). This study uses a combination of in vitro evolution and metabolic rescue experiments to demonstrate that a new antimicrobial resistance mechanism — undetectable using traditional laboratory testing methods — is responsible for high levels of resistance to sulfamethoxazole in GAS.\n\nGutmann, L. & Tomasz, A. Penicillin-resistant and penicillin-tolerant mutants of Group A streptococci. Antimicrob. Agents Chemother. 22, 128–136 (1982).\n\nOlsen, R. J., Zhu, L. C. & Musser, J. M. A single amino acid replacement in penicillin-binding protein 2X in Streptococcus pyogenes significantly increases fitness on subtherapeutic benzylpenicillin treatment in a mouse model of necrotizing myositis. Am. J. Pathol. 190, 1625–1631 (2020).\n\nFood and Drug Administration, HHS. Revocation of status of specific products; Group A Streptococcus. Direct final rule. Fed. Regist. 70, 72197–72199 (2005).\n\nPastural, É. et al. Safety and immunogenicity of a 30-valent M protein-based Group A streptococcal vaccine in healthy adult volunteers: a randomized, controlled phase I study. Vaccine 38, 1384–1392 (2020).\n\nDale, J. B., Penfound, T. A., Chiang, E. Y. & Walton, W. J. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of Group A streptococci. Vaccine 29, 8175–8178 (2011).\n\nSanderson-Smith, M. et al. A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development. J. Infect. Dis. 210, 1325–1338 (2014).\n\nDale, J. B. et al. Potential coverage of a multivalent M protein-based Group A streptococcal vaccine. Vaccine 31, 1576–1581 (2013).\n\nEngel, M. E. et al. Group A streptococcal emm type prevalence among symptomatic children in Cape Town and potential vaccine coverage. Pediatr. Infect. Dis. J. 33, 208–210 (2014).\n\nGiffard, P. M., Tong, S. Y. C., Holt, D. C., Ralph, A. P. & Currie, B. J. Concerns for efficacy of a 30-valent M-protein-based Streptococcus pyogenes vaccine in regions with high rates of rheumatic heart disease. PLoS Negl. Trop. Dis. 13, e0007511 (2019).\n\nSekuloski, S. et al. Evaluation of safety and immunogenicity of a Group A Streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS ONE 13, e0198658 (2018).\n\nPandey, M. et al. Combinatorial synthetic peptide vaccine strategy protects against hypervirulent CovR/S mutant streptococci. J. Immunol. 196, 3364–3374 (2016).\n\nPostol, E. et al. StreptInCor: a candidate vaccine epitope against S. pyogenes infections induces protection in outbred mice. PLoS ONE 8, e60969 (2013).\n\nOzberk, V. et al. Prime-pull immunization with a bivalent M-protein and Spy-CEP peptide vaccine adjuvanted with CAF®01 liposomes induces both mucosal and peripheral protection from covR/S mutant Streptococcus pyogenes. mBio 12, e03537-20 (2021).\n\nReynolds, S. et al. Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines. Sci. Rep. 11, 127 (2021).\n\nPostol, E. et al. Group A Streptococcus adsorbed vaccine: repeated intramuscular dose toxicity test in minipigs. Sci. Rep. 9, 9733 (2019).\n\nBensi, G. et al. Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case. Mol. Cell. Proteom. 11, M111.015693 (2012).\n\nGao, N. J. et al. Site-specific conjugation of cell wall polyrhamnose to protein SpyAD envisioning a safe universal Group A streptococcal vaccine. Infect. Microbes Dis. 3, 87 (2021).\n\nRivera-Hernandez, T. et al. Differing efficacies of lead Group A streptococcal vaccine candidates and full-length M protein in cutaneous and invasive disease models. mBio 7, e00618-16 (2016).\n\nRivera-Hernandez, T. et al. Vaccine-induced TH1-type response protects against invasive Group A Streptococcus infection in the absence of opsonizing antibodies. mBio 11, e00122-20 (2020).\n\nBi, S. et al. A multicomponent vaccine provides immunity against local and systemic infections by Group A Streptococcus across serotypes. mBio 10, e02600–e02619 (2019).\n\nReglinski, M., Lynskey, N. N., Choi, Y. J., Edwards, R. J. & Sriskandan, S. Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG. J. Infect. 72, 450–459 (2016).\n\nLoh, J. M. S. et al. A multivalent T-antigen-based vaccine for Group A Streptococcus. Sci. Rep. 11, 4353 (2021).\n\nWorld Health Organization. Rheumatic fever and rheumatic heart disease. Report by the Director General. Seventy-First World Health Assembly (WHO, 2018).\n\nAndrejko, K., Whittles, L. K. & Lewnard, J. A. Health-economic value of vaccination against Group A Streptococcus in the United States. Clin. Infect. Dis. 74, 983–992 (2022).\n\nMills, J.-L. S. et al. M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP). NPJ Vaccines 5, 74 (2020).\n\nRivera-Hernandez, T. & Walker, M. J. Humanized plasminogen mouse model to study Group A Streptococcus invasive disease. Methods Mol. Biol. 2136, 309–316 (2020).\n\nPandey, M. & Good, M. F. A superficial skin scarification method in mice to mimic Streptococcus pyogenes skin infection in humans. Methods Mol. Biol. 2136, 287–301 (2020).\n\nKonrad, P., Hufnagel, M., Berner, R. & Toepfner, N. Long-term, single-center surveillance of non-invasive Group A streptococcal (GAS) infections, emm types and emm clusters. Eur. J. Clin. Microbiol. Infect. Dis. 39, 273–280 (2020).\n\nPfoh, E., Wessels, M. R., Goldmann, D. & Lee, G. M. Burden and economic cost of Group A streptococcal pharyngitis. Pediatrics 121, 229–234 (2008).\n\nMetzgar, D. & Zampolli, A. The M protein of Group A Streptococcus is a key virulence factor and a clinically relevant strain identification marker. Virulence 2, 402–412 (2011).\n\nCarapetis, J. R., Steer, A. C., Mulholland, E. K. & Weber, M. The global burden of Group A streptococcal diseases. Lancet Infect. Dis. 5, 685–694 (2005). This paper is a comprehensive epidemiological analysis of the global health burden of GAS diseases.\n\nTibazarwa, K. B., Volmink, J. A. & Mayosi, B. M. Incidence of acute rheumatic fever in the world: a systematic review of population-based studies. Heart 94, 1534–1540 (2008).\n\nWatkins, D., Baker, M. G., Kumar, R. K. & Parks, T. in Acute Rheumatic Fever and Rheumatic Heart Disease Ch. 1 (eds Dougherty, S., Carapetis, J., Zühlke, L. & Wilson, N.) 1–18 (Elsevier, 2021).\n\nInstitute for Health Metrics and Evaluation, University of Washington. GBD results. IHME http://vizhub.healthdata.org/gbd-results (2022).\n\nSatoskar, A. A., Parikh, S. V. & Nadasdy, T. Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis. Nat. Rev. Nephrol. 16, 32–50 (2020).\n\nParks, T., Barrett, L. & Jones, N. Invasive streptococcal disease: a review for clinicians. Br. Med. Bull. 115, 77–89 (2015).\n\nRantala, S. et al. Streptococcus pyogenes bacteraemia, emm types and superantigen profiles. Eur. J. Clin. Microbiol. Infect. Dis. 31, 859–865 (2012).\n\nFriães, A., Melo-Cristino, J. & Ramirez, M., & Portuguese Group for the Study of Streptococcal Infections. Changes in emm types and superantigen gene content of Streptococcus pyogenes causing invasive infections in Portugal. Sci. Rep. 9, 18051 (2019).\n\nRaff, A. B. & Kroshinsky, D. Cellulitis: a review. JAMA 316, 325–337 (2016).\n\nSriskandan, S. Severe peripartum sepsis. J. R. Coll. Physicians Edinb. 41, 339–346 (2011).\n\nHamilton, S. M., Stevens, D. L. & Bryant, A. E. Pregnancy-related group a streptococcal infections: temporal relationships between bacterial acquisition, infection onset, clinical findings, and outcome. Clin. Infect. Dis. 57, 870–876 (2013).\n\nParks, T., Wilson, C., Curtis, N., Norrby-Teglund, A. & Sriskandan, S. Polyspecific intravenous immunoglobulin in clindamycin-treated patients with streptococcal toxic shock syndrome: a systematic review and meta-analysis. Clin. Infect. Dis. 67, 1434–1436 (2018).\n\nKotloff, K. L. et al. Safety and immunogenicity of a recombinant multivalent Group A streptococcal vaccine in healthy adults: phase 1 trial. JAMA 292, 709–715 (2004).\n\nMcNeil, S. A. et al. Safety and immunogenicity of 26-valent Group A Streptococcus vaccine in healthy adult volunteers. Clin. Infect. Dis. 41, 1114–1122 (2005)."
    }
}